These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12445247)

  • 41. Carboplatin and short-infusion paclitaxel in high-risk and advanced-stage ovarian carcinoma.
    Coleman RL; Bagnell KG; Townley PM
    Cancer J Sci Am; 1997; 3(4):246-53. PubMed ID: 9263631
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase II study.
    Miglietta L; Amoroso D; Bruzzone M; Granetto C; Catsafados E; Mammoliti S; Guarneri D; Pedulla F; Foglia G; Ragni N; Martini MC; Brema F; Addamo G; Moraglio L; Pastorino G; Boccardo F
    Oncology; 1997; 54(2):102-7. PubMed ID: 9075779
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer.
    Sorbe B; Graflund M; Horvath G; Swahn M; Boman K; Bangshöj R; Lood M; Malmström H
    Int J Gynecol Cancer; 2012 Jan; 22(1):47-53. PubMed ID: 22193643
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer.
    Gershenson DM; Morris M; Burke TW; Levenback C; Kavanagh JJ; Fromm GL; Silva EG; Warner D; Wharton JT
    Gynecol Oncol; 1995 Sep; 58(3):349-55. PubMed ID: 7672700
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer.
    Shapiro JD; Rothenberg ML; Sarosy GA; Steinberg SM; Adamo DO; Reed E; Ozols RF; Kohn EC
    Cancer; 1998 Nov; 83(9):1980-8. PubMed ID: 9806657
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
    Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
    Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer.
    Nagao S; Fujiwara K; Ohishi R; Nakanishi Y; Iwasa N; Shimizu M; Goto T; Shimoya K
    Int J Gynecol Cancer; 2008; 18(6):1210-4. PubMed ID: 18284454
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a gynecologic oncology group study.
    Schilder RJ; Brady MF; Spriggs D; Shea T
    Gynecol Oncol; 2003 Jan; 88(1):3-8. PubMed ID: 12504619
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer.
    De Placido S; Tramontana S; Ferrari E; De Matteis A; Lauria R; Perrone F; Bianco AR; Gallo C; Ricchi P; De Placido G; Pignata S;
    Anticancer Res; 2000; 20(5C):4023-9. PubMed ID: 11268496
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ten-year results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer.
    Marth C; Tropé C; Vergote IB; Kristensen GB
    Eur J Cancer; 1998 Jul; 34(8):1175-80. PubMed ID: 9849475
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study.
    Oaknin A; Roda D; González-Martín A; Chiva L; García-Donas J; de Juan A; Redondo A; Martínez S; García Y; Catot S; Ponce J; Del Campo JM; Cervantes A; Poveda A
    Int J Gynecol Cancer; 2011 Aug; 21(6):1048-55. PubMed ID: 21738038
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized study comparing carboplatin/cyclophosphamide and cisplatin/cyclophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease. German Ovarian Cancer Study Group (GOCA).
    Meerpohl HG; Sauerbrei W; Kühnle H; Schumacher M; Pfleiderer A
    Gynecol Oncol; 1997 Jul; 66(1):75-84. PubMed ID: 9234925
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
    du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
    Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chemotherapy, early surgical reassessment, and hyperfractionated abdominal radiotherapy in stage III ovarian cancer: results of a gynecologic oncology group study.
    Randall ME; Barrett RJ; Spirtos NM; Chalas E; Homesley HD; Lentz SL; Hanna M
    Int J Radiat Oncol Biol Phys; 1996 Jan; 34(1):139-47. PubMed ID: 12118543
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
    Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
    Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chemotherapy with high dose ifosfamide/mesna plus cisplatin for the treatment of ovarian cancer: a study of the Grupo de Estudio y Tratamiento Latino-Americano del Cancer.
    Araujo CE; Cervellino JC; Pirisi C; Pannunzio O; Callegari J
    J Surg Oncol; 1991 Mar; 46(3):198-202. PubMed ID: 1901372
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
    Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
    Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.